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Abstract 
Background: Hereditary angioedema (HAE) is characterized by recurrent attacks of subcutaneous or submucosal 
edema. Attacks are unpredictable, debilitating, and have a significant impact on quality of life. Patients may be 
prescribed prophylactic therapy to prevent angioedema attacks. Current prophylactic treatments may be difficult to 
administer (i.e., intravenously), require frequent administrations or are not well tolerated, and breakthrough attacks 
may still occur frequently. Lanadelumab is a subcutaneously-administered monoclonal antibody inhibitor of plasma 
kallikrein in clinical development for prophylaxis of hereditary angioedema attacks. A Phase 1b study supported its 
efficacy in preventing attacks. A Phase 3, randomized, double-blind, placebo-controlled, parallel-arm study has been 
completed and an open-label extension is currently ongoing.
Methods/design: The primary objective of the open-label extension is to evaluate the long-term safety of repeated 
subcutaneous administrations of lanadelumab in patients with type I/II HAE. Secondary objectives include evalua-
tion of efficacy and time to first angioedema attack to determine outer bounds of the dosing interval. The study will 
also evaluate immunogenicity, pharmacokinetics/pharmacodynamics, quality of life, characteristics of breakthrough 
attacks, ease of self-administration, and safety/efficacy in patients who switch to lanadelumab from another pro-
phylactic therapy. The open-label extension will enroll patients who completed the double-blind study (“rollover 
patients”) and those who did not participate in the double-blind study (“non-rollover patients”), which includes 
patients who may or may not be currently using another prophylactic therapy. Rollover patients will receive a single 
300 mg dose of lanadelumab on Day 0 and the second dose after the patient’s first confirmed angioedema attack. 
Thereafter, lanadelumab will be administered every 2 weeks. Non-rollover patients will receive 300 mg lanadelumab 
every 2 weeks regardless of the first attack. All patients will receive their last dose on Day 350 (maximum of 26 doses), 
and will then undergo a 4-week follow-up.
Discussion: Prevention of attacks can reduce the burden of illness associated with HAE. Prophylactic therapy requires 
extended, repeated dosing and the results of this study will provide important data on the long-term safety and 
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Background
Hereditary angioedema (HAE) is a rare genetic disorder 
that affects an estimated 1 in 50,000 individuals [1]. It is 
characterized by recurrent debilitating attacks of subcu-
taneous or submucosal edema, most often affecting the 
face, gastrointestinal tract, extremities, genitalia, and 
larynx [2]. Patients experience symptoms of localized 
swelling and pain. HAE type I and type II are caused by 
a deficiency in the quantity or functional activity of C1 
inhibitor (C1-INH), which results in dysregulation of 
plasma kallikrein activity and excessive release of the 
vasodilator bradykinin from high molecular weight 
kininogen (HMWK) [1, 3].
As angioedema attacks are unpredictable, and those 
affecting the larynx can be life-threatening, one treatment 
strategy for HAE involves the use of prophylactic agents 
to prevent angioedema attacks. Current long-term pro-
phylactic therapies include the replacement of C1-INH 
with plasma-derived C1-INH or treatment with attenu-
ated androgens (Table 1). However, C1-INH replacement 
requires frequent intravenous administration, which 
may be inconvenient and difficult for some patients, and 
androgens are limited by a poor safety profile, especially 
for female and pediatric patients [1, 4].
Lanadelumab (DX-2930) is a fully human monoclo-
nal antibody inhibitor of plasma kallikrein. Inhibition of 
plasma kallikrein is an attractive and rational therapeutic 
strategy for HAE as it prevents the production of brady-
kinin. Lanadelumab is a highly potent  (Ki  =  125  pM), 
specific, and rapid inhibitor of plasma kallikrein that was 
discovered by phage display technology and is produced 
in Chinese Hamster Ovary cells using standard meth-
ods [5]. It received fast-track and breakthrough therapy 
designations from the US Food and Drug Administra-
tion and is currently in Phase 3 clinical development for 
prophylaxis against HAE attacks. Data from two Phase 1 
studies did not identify any safety concerns (Table 2) [6, 
7]. A Phase 1b study in patients with HAE treated with 
two subcutaneous doses of 300 and 400 mg lanadelumab 
suggested efficacy in preventing angioedema attacks [7].
A pivotal, Phase 3, multicenter, randomized, double-
blind, placebo-controlled study (HELP Study [DX-2930-
03; NCT02586805]) enrolling up to 120 patients to further 
assess the safety and efficacy of lanadelumab has been 
completed [8]. Patients who completed the double-blind 
study were offered the option of continuing into the long-
term open-label extension (HELP Study Extension [DX-
2930-04; NCT02741596]) [9]. In addition, the open-label 
extension study will enroll 100 patients who did not par-
ticipate in the double-blind study and who may or may 
not be currently receiving prophylactic treatment. The 
open-label extension study will evaluate the long-term 
safety of subcutaneously administered lanadelumab (over 
12–18  months of exposure across both studies) and its 
long-term efficacy in preventing angioedema attacks.
Methods/design
Objectives
The primary objective of this study is to evaluate the 
long-term safety of repeated subcutaneous administra-
tions of lanadelumab in patients with HAE.
Secondary objectives include evaluation of the long-
term efficacy of lanadelumab in preventing HAE attacks 
and the outer bounds of dosing frequency (i.e., the dura-
tion of its clinical effect) by assessing the length of time 
between a rollover patient’s first open-label dose of 
lanadelumab and their first reported HAE attack.
Tertiary objectives include evaluation of immunogenic-
ity, health-related quality of life, the pharmacokinetic/
pharmacodynamic profile of lanadelumab, safety and effi-
cacy associated with switching from another long-term 
prophylactic therapy to lanadelumab, characteristics of 
breakthrough attacks compared with historical baseline, 
and experience with self-administration of lanadelumab.
Study setting
A total of 43 study sites are planned across North Amer-
ica, Europe, and the Middle East. Patients may, after 
receiving the first two doses of study drug at the site and 
after completing training, self-administer lanadelumab 
off site.
Study design
The open-label extension study will consist of patients 
who complete the double-blind study (rollover patients) 
and additional patients who are not part of the double-
blind study (non-rollover patients). All patients will 
receive open-label lanadelumab every 2  weeks over a 
364-day treatment period, followed by a 4-week safety 
follow-up before discharge from the study.
efficacy of lanadelumab, a monoclonal antibody inhibitor of plasma kallikrein for subcutaneous administration for the 
treatment of HAE.
Trial registration NCT02741596
Keywords: Hereditary angioedema, Lanadelumab, Monoclonal antibody, Bradykinin, Plasma kallikrein, Prophylaxis, 
C1-inhibitor, Rare disease, Orphan disease
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Study patients
All patients enrolled in the double-blind study will be 
eligible for rollover into the open-label extension study 
(Fig. 1). Patients who discontinue from the double-blind 
study after enrollment will not be eligible to enroll in the 
open-label extension study.
Up to 100 non-rollover patients will also be screened 
and enrolled in the open-label extension study. Among 
these will be patients who are using another long-term 
prophylactic agent in order to evaluate the efficacy and 
safety of switching from another prophylactic therapy to 
lanadelumab. Patients who did not qualify for the double-
blind study may screen for eligibility in the open-label 
extension.
The study will aim to enroll at least 15 patients who are 
12–17 years of age.
Inclusion criteria
Patients must meet the following criteria to be enrolled 
in the study:
Placebo Lanadelumab 300 mgevery 4 weeks
Lanadelumab 300 mg
every 2 weeks
Treatment
26 weeks (Day 1–182)
8-week follow-up
OLE study
Lanadelumab 300 mg single dose
Day 0a
Lanadelumab 300 mg
single dose after first
HAE attack
≥Day 10 
Lanadelumab 300 mg
every 2 weeks
Last dose on Day 350
Day 378–392
4-week follow-up
Lanadelumab 300 mg
first dose
Day 0 
Screening
(patients not rolled 
over from DB study)
4 weeks
DB study OLE study
Lanadelumab 150 mg
every 4 weeks
Screening 
Run-in 
LTP washout
2 weeks
4 weeks
Fig. 1 Overview of study design. DB double-blind; HAE hereditary angioedema, LTP long-term prophylaxis; OLE open-label extension. aFor rollover 
patients, Day 0 of the open-label extension study coincides with Day 182 of the double-blind study
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1. Male or female patients who are ≥ 12 years of age at 
the time of screening.
2. Patients must have documented confirmation of type 
I/II HAE. Confirmation will require (1) a clinical 
history consistent with HAE, (2) diagnostic testing 
results that confirm HAE (C1-INH functional level 
< 40% of normal. Patients with functional C1-INH at 
40–50% of normal may be enrolled if they also have a 
C4 level below the normal range), and (3) either age 
of onset of first angioedema symptoms ≤ 30 years, a 
family history consistent with HAE, or C1q within 
normal range.
3. Patients must have a historical baseline attack rate of 
at least one attack per 12 weeks.
4. Patients and/or their caregivers (as appropriate) must 
be able to provide informed consent or assent (as 
appropriate).
5. Patients must adhere to contraception requirements 
for the duration of the study.
Exclusion criteria
Patients who meet any of the following will be excluded 
from the study:
1. Discontinued from the double-blind study for any 
reason.
2. If rolling over from the double-blind study, the pres-
ence of any safety concerns that would preclude par-
ticipation in the open-label extension study.
3. Concomitant diagnosis of another form of chronic 
recurrent angioedema such as acquired angi-
oedema, HAE with normal C1-INH, idiopathic 
angioedema, or recurrent angioedema associated 
with urticaria.
4. Exposure to an investigational drug (excluding 
lanadelumab or other HAE therapies) or investiga-
tional device within 4 weeks prior to screening.
5. Exposure to angiotensin-converting enzyme inhibi-
tors within 4  weeks prior to screening or exposure 
to any newly initiated or modified dose of systemic 
estrogen-containing medications within 3  months 
prior to screening.
6. Unwilling to discontinue use of long-term prophy-
laxis (C1-INH, androgens or anti-fibrinolytics) 
within 3 weeks after starting lanadelumab treatment.
7. Presence of liver function abnormalities.
8. Pregnant or breastfeeding.
9. Presence of any condition that, in the opinion of 
the investigator or sponsor, may compromise the 
patient’s safety or compliance, preclude successful 
conduct of the study or interfere with interpretation 
of the results.
Interventions
Patients will receive open-label 300 mg (2 mL) subcuta-
neous injections of lanadelumab every 2  weeks, as this 
dose is anticipated to be effective and safe. If at any time 
an important dose-related safety signal is identified from 
either the double-blind or the open-label extension study, 
patients who have not completed the study and any sub-
sequent patients may be switched to a different dose and/
or dosing frequency. In addition, a different dose and/or 
frequency may be used based on the efficacy and safety 
results of the double-blind study.
For rollover patients, a single dose of lanadelumab will 
be administered on Day 0 of the open-label extension 
study (coinciding with Day 182 of the double-blind study). 
The second dose of lanadelumab will not be administered 
until after the first investigator-confirmed angioedema 
attack. The day of the second dose will vary depending on 
when the first attack occurs, but there must be a minimum 
of 10 days between the Day 0 dose and the second dose. 
Thus, patients who experience an attack within 10 days of 
the first dose will not receive the second dose until Day 
10. Thereafter, 300 mg lanadelumab will be administered 
every 2 weeks, with the final study dose administered on 
Day 350, for a maximum of 26 doses. All patients, caregiv-
ers, investigators, and study site personnel will remain 
blinded to the double-blind treatment assignment until 
the conclusion of the open-label extension study.
Non-rollover patients will receive their first open-label 
300  mg dose of lanadelumab on Day 0, with dosing for 
the study continuing every 2 weeks until Day 350, regard-
less of the first attack, for a total of 26 doses.
Patients who are considered suitable candidates may 
qualify to self-administer lanadelumab after the second 
dose. Patients must complete appropriate training for 
self-administration and demonstrate the comprehension 
and technique to self-administer.
Concomitant therapies
Therapies for coexisting conditions, including the treat-
ment of angioedema attacks and short-term prophylaxis, 
are permitted as described below.
Long-term prophylaxis will not be permitted once it 
has been discontinued, as described below. Androgens 
may not be used for HAE or for any medical condition. 
Use of angiotensin-converting enzyme inhibitors, estro-
gen-containing medications with systemic absorption, 
and any other investigational drug or device is not per-
mitted, as described under Exclusion criteria.
Current prophylactic therapies
In the absence of formal guidelines for withdrawal of 
long-term prophylaxis, our approach is based on clinical 
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expert recommendations. Current long-term prophy-
lactic therapies will be tapered off. Use of C1-INH may 
continue until Day 15. Androgens or anti-fibrinolytics 
may also be used up to Day 15 but, if necessary, may 
be extended until a maximum of 3  weeks after the first 
lanadelumab dose.
The use of C1-INH as a short-term (pre-procedure) 
prophylactic treatment for HAE will be permitted if med-
ically indicated.
Management of angioedema attacks
Angioedema attacks that occur during the study will 
be managed in accordance with the investigator’s usual 
standard of care, including use of acute therapies that 
the investigator deems to be medically appropriate. Use 
of C1-INH will be permitted for treatment for an angi-
oedema attack. Administration of lanadelumab and study 
procedures will continue as planned in the protocol, even 
if the patient has symptoms of an angioedema attack the 
day of lanadelumab administration and/or receives treat-
ment for an angioedema attack.
Outcomes
All study activities are shown in Additional file 1: Table 
S1.
Safety assessments will include the following:
  • Adverse events, including serious adverse events and 
adverse events of special interest, such as hypersensi-
tivity reactions and events of disordered coagulation 
(bleeding, hypercoagulation). HAE attacks that occur 
during the study will be captured as adverse events
  • Vital signs (blood pressure, heart rate, body tempera-
ture, respiratory rate)
  • Clinical laboratory tests (hematology, serum chemis-
try, coagulation, urinalysis)
  • Physical examination
  • 12-lead electrocardiogram.
The following information will be collected for HAE 
attacks that occur during the study:
  • Date and time the attack symptoms started
  • Description of symptoms experienced, including 
location(s)
  • Impact on activity (work, school, social interactions)
  • Assistance or medical intervention required (hospi-
talizations, additional laboratory tests, emergency 
department visits)
  • Any medications used to treat the attack (both pre-
scription and over-the-counter)
  • If the attack resolved, date and time of symptom res-
olution.
Patients or their caregivers must notify and report 
details to the study site within 72  h of the onset of an 
angioedema attack. If desired, a memory aid such as a 
diary may be used to assist in tracking HAE attacks. To 
be confirmed as an angioedema attack, the event must 
have symptoms or signs consistent with an angioedema 
attack. The investigator or physician designee will clini-
cally determine whether the event did or did not repre-
sent an angioedema attack. To be counted as a unique 
angioedema attack distinct from the previous angi-
oedema attack, the new symptoms must occur at least 
24 h after resolution of the symptoms of the prior angi-
oedema attack.
The efficacy of lanadelumab will be evaluated using 
the angioedema attack data during the treatment period 
(Day 0 through Day 364). Efficacy end points will include 
the following:
  • Time to first attack for rollover patients
  • Number of investigator-confirmed attacks
  • Number of investigator-confirmed attacks requiring 
acute treatment
  • Number of moderate and severe attacks. Attack 
severity will be assessed as mild (transient or mild 
discomfort), moderate (mild to moderate limita-
tion in activity; some assistance required) or severe 
(marked limitation in activity; assistance required).
  • Number of high-morbidity attacks, which are defined 
as any attack with at least one of the following char-
acteristics: severe, results in hospitalization, hemody-
namically significant or upper airway (laryngeal).
Blood samples will be collected at various time points 
during the study to measure the following:
  • Plasma lanadelumab concentrations to obtain a phar-
macokinetic profile [7]
  • Pharmacodynamic biomarkers (plasma kallikrein 
activity, as measured by cleaved HMWK levels) [7]
  • Presence of anti-drug antibodies. Samples that are 
confirmed positive for anti-drug antibodies will be 
further analyzed for neutralizing antibodies. The 
method of analysis has been previously described [7]
  • Functional C1-INH, C4, and C1q levels for eligibility 
assessment at screening for non-rollover patients.
Patient quality of life will be assessed using the 
following:
  • Angioedema Quality of Life Questionnaire (AE-QoL) 
[10]
  • EuroQol 5-Dimensional 5-Level Measure (EQ-
5D-5L) [11]
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  • Work Productivity and Activity Impairment Ques-
tionnaire: General Health (WPAI-GH) [12]
  • Hospital Anxiety and Depression Scale (HADS) [13]
  • 12 Item Short Form Survey (SF-12) [14]
If applicable, patients will be surveyed on their experi-
ence with self-administration and subcutaneous injection 
of lanadelumab every 6 months during the study. Patients 
who previously received long-term prophylaxis with 
C1-INH products by intravenous administration will 
be asked to indicate the preferred route for medication 
administration.
Sample size
The sample size for this single arm, open-label study is 
not based on a formal statistical sample size calculation. 
This study does not have a control arm, thus no formal 
statistical hypothesis testing will be performed. All p-val-
ues will be considered descriptive.
Individual stopping rules
Dosing for any individual patient will be discontinued if 
the patient experiences a serious adverse event or clini-
cally significant non-serious adverse event that is related 
to lanadelumab treatment and that, in the opinion of the 
investigator or the independent Data and Safety Moni-
toring Board, warrants discontinuation from further dos-
ing for that patient’s well-being. Patients who discontinue 
from the study will undergo, if possible, all assessments 
and procedures scheduled for Day 378–392 (see Addi-
tional file 1: Table S1).
Treatment compliance
All doses of open-label lanadelumab administered at the 
investigational site will be given under the direct supervi-
sion of the investigator or designee. Doses that are self-
administered off site will be confirmed by site personnel 
within approximately 3  days of the planned administra-
tion. Patients will be contacted to ensure the administra-
tion occurred, to collect information on adverse events 
and concomitant medications, and to ensure all attacks 
have been appropriately documented.
Data analysis
The safety population will include all patients who 
received any study drug after entering the open-label 
extension study. The rollover safety population is the sub-
set of patients who participated in the double-blind study 
and received any study drug after entering the open-label 
extension study. The non-rollover safety population is the 
subset of patients who directly entered the open-label 
extension study and subsequently received any study 
drug.
All available data will be included in the analysis. No 
imputation of missing data will be performed. Summary 
tabulations conducted with the non-rollover safety popu-
lation will be presented by patient’s type of LTP prior to 
study entry.
AEs will be coded using the Medical Dictionary for 
Regulatory Activities and will be summarized by sys-
tem organ class and preferred term for each population. 
The number of events and the number and percentage 
of patients with any treatment-emergent adverse event, 
serious adverse event, severe adverse event, or adverse 
event of special interest will be summarized according to 
relatedness to treatment.
Actual values and change from baseline in clinical labo-
ratory test results and vital signs will be summarized by 
study visit. The number and percentage of patients with 
normal, abnormal, and abnormal clinically significant 
electrocardiogram results will be summarized by study 
visit.
Time to the first investigator-confirmed attack will be 
analyzed using the rollover safety population. Patients 
who discontinue the study prior to experiencing their 
first confirmed attack will be censored at the date and 
time of discontinuation. Data will be summarized using 
Kaplan–Meier methods. The number of angioedema 
attacks from Day 0 through Day 364 will be expressed as 
a monthly angioedema attack rate and will be analyzed 
for each analysis population. The monthly attack rate will 
be calculated for each patient as the number of attacks 
occurring during the treatment period divided by the 
number of days the patient contributed to the treatment 
period multiplied by 28 days. The attack rate will also be 
analyzed by subgroups, including age group, sex, race, 
weight, body mass index, baseline angioedema attack 
rate, HAE type, geographic region, and administration 
type. Sensitivity analyses will be performed on the attack 
rate to evaluate the robustness of the results.
Plasma lanadelumab concentrations and plasma kal-
likrein activity endpoints will be summarized by nominal 
sampling times. The number and percentage of patients 
with positive antibodies will be summarized by study 
visit and overall.
Quality of life assessments will be summarized by study 
visit.
Discussion
This study will provide important information on the 
long-term safety and efficacy of lanadelumab in pre-
venting angioedema attacks. An evaluation of lanade-
lumab over an extended period is valuable, as real-world 
use of lanadelumab would involve ongoing, repeated 
dosing. To date, clinical studies for lanadelumab have 
not indicated any safety concerns and have suggested 
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preliminary data for efficacy in preventing angioedema 
attacks in patients with HAE. In a Phase 1a study, 32 
healthy volunteers received a single dose of lanadelumab 
(dose range 6.2–302  mg) or placebo [6]. All doses were 
well tolerated, there were no deaths, serious adverse 
events, or discontinuations owing to adverse events, and 
treatment-emergent adverse events were comparable 
between subjects who received lanadelumab and those 
who received placebo. None of the subjects were posi-
tive for anti-drug antibodies. In a Phase 1b study, patients 
with HAE received two doses of lanadelumab (30, 100, 
300 or 400  mg) or placebo, administered 14  days apart. 
The rate of adverse events was similar in lanadelumab-
treated patients compared with those who received pla-
cebo, and the results of other safety outcome measures 
showed that lanadelumab was safe up to 400  mg. Non-
neutralizing anti-drug antibodies were detected in a total 
of two patients: one in the 30 mg dose group, and one in 
the 400 mg dose group. Furthermore, the attack rate was 
reduced by 100 and 88% in patients who received 300 mg 
and 400  mg lanadelumab, respectively, relative to pla-
cebo. The reduction in attack rate coincided with drug 
exposure and a decrease in cleaved HMWK levels, pro-
viding proof of concept for the mechanism of action of 
lanadelumab [7].
The double-blind study will assess the efficacy and 
safety of lanadelumab over 26  weeks of treatment. Fol-
lowing the double-blind study, results from the open-
label extension study will confirm findings on safety, 
efficacy, and pharmacodynamic effect from prior clinical 
studies. By delaying the second dose for rollover patients 
until the first attack has occurred, the study design incor-
porates a unique feature to investigate the pharmaco-
dynamic effect of lanadelumab. However, the design is 
not adaptable in that individual adjustments in the dos-
ing interval will not be made based upon each patient’s 
response. The open-label extension study will also assess 
the safety, efficacy, and impact on quality of life of lanade-
lumab for patients who are currently using other long-
term prophylactic therapies. Patients with HAE have a 
strong preference for self-administration of therapeutics 
[15, 16], and the open-label extension study will evaluate 
patients’ experience with self-administration of lanade-
lumab. This will help to assess treatment burden and 
potential ease and convenience of lanadelumab therapy.
A recognized potential limitation of this study, as for 
any controlled clinical trial with established inclusion 
and exclusion criteria for enrollment, is the possibility of 
investigator bias introduced by study patient selection. 
Some degree of selection bias may inherently be intro-
duced as part of the study enrollment process. These 
potential limitations will be acknowledged and addressed 
as part of the Discussion when results are available.
Although current prophylactic treatments for HAE 
may be effective at reducing the frequency, duration, and 
severity of HAE attacks, there remains an unmet need for 
more effective and less burdensome treatment of attacks. 
The key attributes for a new prophylactic therapy would 
be improved efficacy (reduced attack frequency and 
increased proportion of patients who are attack-free), 
safety and tolerability, and patient convenience in order 
to ease both the burden of illness and treatment for indi-
viduals with HAE.
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